BIND Therapeutics barasertib data positive, says JMP Securities JMP Securities notes that pre-clinical studies of BIND's barasertib showed enhanced anti-tumor activity and reduced bone marrow toxicity. The firm thinks the company could overcome the need for lengthy drug infusion and high rates of febrile neutropenia, shown in a previous studiy, by extending the half-life of the drug. The firm reiterates a $30 price target and Outperform rating on the stock.
BIND Therapeutics data encouraging, says JMP Securities JMP Securities believes that data for BIND's BIND-014 showed encouraging evidence of activity and overall survival in difficult-to-treat subsets of non-small cell lung cancer. The firm reiterates a $30 price target and Outperform rating on BIND.